Sanofi (SNY) Income Statement

NASDAQ: SNYRevenue, profits, margins and EPS over 10 years.

SNY 2025 at a glance

Fiscal year ended December 31, 2025 · euros
Revenue+5.5%
€46.72B
2025 · hover or tap a bar for each year
2016: €34.70B (−0.5%)2017: €36.22B (+4.4%)2018: €35.68B (−1.5%)2019: €37.63B (+5.5%)2020: €37.37B (−0.7%)2021: €39.17B (+4.8%)2022: €40.56B (+3.5%)2023: €41.62B (+2.6%)2024: €44.29B (+6.4%)2025: €46.72B (+5.5%)
20162025
Gross profit+8.3%
€33.67B
2025 · hover or tap a bar for each year
2016: €24.00B (+0.2%)2017: €24.61B (+2.6%)2018: €24.24B (−1.5%)2019: €25.65B (+5.8%)2020: €25.21B (−1.7%)2021: €26.92B (+6.8%)2022: €28.68B (+6.5%)2023: €28.99B (+1.1%)2024: €31.08B (+7.2%)2025: €33.67B (+8.3%)
20162025
Operating income+32.3%
€9.60B
2025 · hover or tap a bar for each year
2016: €6.53B (+16.1%)2017: €5.80B (−11.1%)2018: €4.68B (−19.4%)2019: €3.05B (−34.8%)2020: €14.11B (+362.6%)2021: €8.13B (−42.4%)2022: €10.16B (+25.1%)2023: €6.96B (−31.5%)2024: €7.25B (+4.2%)2025: €9.60B (+32.3%)
20162025
Net income+40.5%
€7.81B
2025 · hover or tap a bar for each year
2016: €4.71B (+9.8%)2017: €8.42B (+78.7%)2018: €4.31B (−48.8%)2019: €2.75B (−36.0%)2020: €12.29B (+346.4%)2021: €6.22B (−49.4%)2022: €8.37B (+34.5%)2023: €5.40B (−35.5%)2024: €5.56B (+3.0%)2025: €7.81B (+40.5%)
20162025
Net profit margin+4.2 pts
16.7%
2025 · hover or tap a point for each year
2016: 13.6% (+1.3 pts)2017: 23.2% (+9.7 pts)2018: 12.1% (−11.2 pts)2019: 7.3% (−4.8 pts)2020: 32.9% (+25.6 pts)2021: 15.9% (−17.0 pts)2022: 20.6% (+4.8 pts)2023: 13.0% (−7.7 pts)2024: 12.6% (−0.4 pts)2025: 16.7% (+4.2 pts)
20162025

SNY revenue and net income

RevenueNet incomeNet margin (right axis)

Where SNY's revenue goes

2025
Revenue
€46.72B100.0%
Cost of revenue
−€13.05B−27.9%
Gross profit
€33.67B72.1%
Research & development
−€7.84B−16.8%
Sales, general & admin
−€10.24B−21.9%
Other operating expenses
−€5.99B−12.8%
Operating income
€9.60B20.5%
Interest & other expense
−€3.58B−7.7%
Income taxes
−€1.04B−2.2%
Net income
€7.81B16.7%

Each bar shows an amount and its share of revenue. SNY kept 16.7% of revenue as net income.

SNY profit margins

GrossOperatingNet

SNY growth rates

to 2025
1 year3 years5 years10 years
Revenue+5.5%+4.8%+4.6%+3.0%
Gross profit+8.3%+5.5%+6.0%+3.5%
Operating income+32.3%−1.9%−7.4%+5.5%
Net income+40.5%−2.3%−8.7%+6.2%

1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.

SNY income statement in euros

2025202420232022202120202019201820172016
Revenue€46.72B€44.29B€41.62B€40.56B€39.17B€37.37B€37.63B€35.68B€36.22B€34.70B
Cost of revenue€13.05B€13.21B€12.63B€11.88B€12.26B€12.16B€11.98B€11.44B€11.61B€10.70B
Gross profit€33.67B€31.08B€28.99B€28.68B€26.92B€25.21B€25.65B€24.24B€24.61B€24.00B
Research & development€7.84B€7.39B€6.51B€6.50B€5.69B€5.53B€6.02B€5.89B€5.47B€5.17B
Sales, general & admin€10.24B€9.18B€10.69B€10.49B€9.55B€1.0M€9.88B€9.93B€10.16B€9.59B
Total operating expenses€24.07B€23.83B€22.03B€18.52B€18.79B€11.10B€22.60B€19.57B€18.80B€17.46B
Operating income€9.60B€7.25B€6.96B€10.16B€8.13B€14.11B€3.05B€4.68B€5.80B€6.53B
Interest income€331.0M€413.0M€546.0M€206.0M€40.0M€53.0M€141.0M€164.0M€147.0M€68.0M
Interest expense€626.0M€622.6M€512.8M€384.8M€377.4M€430.8M€536.3M€486.5M€333.4M€399.5M
Income before taxes€6.02B€6.76B€6.12B€9.99B€7.84B€14.14B€3.01B€4.90B€5.62B€5.81B
Income taxes€1.04B€1.20B€1.02B€1.91B€1.56B€1.81B€121.0M€481.0M€1.72B€1.32B
Net income€7.81B€5.56B€5.40B€8.37B€6.22B€12.29B€2.75B€4.31B€8.42B€4.71B
EBITDA€12.48B€11.03B€11.39B€13.51B€11.54B€17.53B€10.66B€9.18B€9.64B€9.90B
Gross margin72.1%70.2%69.7%70.7%68.7%67.5%68.2%67.9%67.9%69.2%
Operating margin20.5%16.4%16.7%25.1%20.7%37.8%8.1%13.1%16.0%18.8%
Net margin16.7%12.6%13.0%20.6%15.9%32.9%7.3%12.1%23.2%13.6%

Quarterly columns are labeled by the month the quarter ended. Figures in euros as reported in SNY's financial statements (latest annual report filed February 17, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.

SNY financial results

In fiscal year 2025 (ended December 31, 2025), Sanofi reported revenue of €46.7 billion, up 5.5% from the year before. It had net income of €7.8 billion (up 40.5%), a net profit margin of 16.7%. Over five years revenue grew at an average rate of 4.6% a year. Figures are in euros, the currency of its financial statements.

See the SNY stock overview for the latest quote and news, or the SNY chart for price history and technical indicators.

SNY income statement FAQ

What is Sanofi's annual revenue?

Sanofi reported total revenue of €46.7 billion for fiscal year 2025, which ended on December 31, 2025. That was up 5.5% from €44.3 billion the previous year.

Is Sanofi profitable?

Yes. Sanofi reported net income of €7.8 billion in fiscal 2025, a net profit margin of 16.7%; its operating margin was 20.5%.

What is Sanofi's gross margin?

Sanofi's gross margin was 72.1% in fiscal 2025: for every $100 of revenue, Sanofi kept $72 after the direct cost of its products and services.

How much does Sanofi spend on research and development?

Sanofi spent €7.8 billion on research and development in fiscal 2025, 16.8% of revenue.

How fast is Sanofi growing?

Revenue grew 4.6% a year on average over the last five fiscal years, from €37.4 billion to €46.7 billion.

When will Sanofi report its next earnings?

Sanofi is expected to report results for the quarter ending September 30, 2026 on October 30, 2026 before the market opens.

When does Sanofi's fiscal year end?

Sanofi's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 17, 2026.

Drug Manufacturers - General income statements